GGrantIndex
Sort

11,323 grants matching glioblastoma

Disease Status Drug Metabolism and New Drug Discovery

$492,552
Irving William Wainer · National Institute On Aging · ZIA · FY2010 · AG

Sialylation in the Maintenance and Metabolic Plasticity of Neural Stem Cell-Like Brain Tumor Cells

$492,216
Anita Borton Hjelmeland · University Of Alabama At Birmingham · R01 · FY2023 · NS

Radiation-induced vascular reprogramming in glioblastoma

$492,144
Harley I Kornblum · University Of California Los Angeles · R01 · FY2022 · NS

Imaging Signaling Changes in Cancer and Treatment

$492,028
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2007 · CA

Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics

$491,992
William R Roush · Scripps Florida · R01 · FY2016 · CA

Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics

$491,992
William R Roush · Scripps Florida · R01 · FY2015 · CA

Ex vivo analysis of human brain tumor cells in a microvascular niche model

$491,875
Rong Fan · Yale University · R01 · FY2024 · CA

Chemical Probes for Metabolic Pathway Discovery in Human Disease

$491,691
Benjamin F Cravatt · Scripps Research Institute, The · R01 · FY2014 · CA

Calcium Channels in Glioblastoma

$491,638
Roger Abounader · University Of Virginia · R01 · FY2024 · NS

Quantitative Biomarker Imaging for Early Therapy Response Assessment in Cancer

$491,577
James M Mountz · University Of Pittsburgh At Pittsburgh · U01 · FY2011 · CA

Targeted Inhibition in Leukemia

$491,521
Nicolas Nassar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · CA

Targeted Inhibition in Leukemia

$491,521
Nicolas Nassar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · CA

Characterizing inhibitors of tyrosine protein kinase ABL1 (ABL1) in human glioblastoma

$491,448
Juan Marugan · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR

Targeting metabolic vulnerabilities in glioblastoma

$490,971
David A. Nathanson · University Of California Los Angeles · R01 · FY2020 · CA

Targeting metabolic vulnerabilities in glioblastoma

$490,971
David A. Nathanson · University Of California Los Angeles · R01 · FY2021 · CA

Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma

$490,899
Brendan A. Harley · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA

Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis

$490,853
Benjamin W. Purow · University Of Virginia · R01 · FY2017 · CA

Physical Limits of Quantitative SPECT

$490,818
Brigham And Women'S Hospital · R01 · FY2002 · EB

Bidirectional interaction of platelets and tumor cells in patients with glioblastoma

$490,666
Erik Sulman · New York University School Of Medicine · R01 · FY2020 · CA

Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma

$490,478
Brendan A. Harley · University Of Illinois At Urbana-Champaign · R01 · FY2023 · CA

Targeting the PI3K Signaling Axis

$490,407
Thomas M Roberts · Massachusetts General Hospital · P50 · FY2014 · CA

MDA-7/IL-24: Therapy of Prostate Cancer

$490,383
Paul B Fisher · Virginia Commonwealth University · P01 · FY2009 · CA

Pre-Clinical Trials of GEM Models for Gliomas

$490,293
Sloan-Kettering Institute For Cancer Res · R01 · FY2004 · CA

The Role of Cellular Receptors Involved in Inflammation and Tumor Progression

$489,899
Ji Ming Wang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Assaying GBM growth and therapy response in single cells and tumorspheres (PQ17)

$489,889
Keith L Ligon · Dana-Farber Cancer Inst · R01 · FY2015 · CA